SCHEMBL15091050

SCHEMBL15091050

C=C(C)c1ccc(N)nc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GABRP O00591 3/20 0.38
GABRD O14764 3/20 0.38
GABRA1 P14867 3/20 0.38
GABRB1 P18505 3/20 0.38
GABRG2 P18507 3/20 0.38
GABRB3 P28472 3/20 0.38
GABRA5 P31644 3/20 0.38
GABRA3 P34903 3/20 0.38
GABRA2 P47869 3/20 0.38
GABRB2 P47870 3/20 0.38
GABRA4 P48169 3/20 0.38
GABRE P78334 3/20 0.38
GABRA6 Q16445 3/20 0.38
GABRG1 Q8N1C3 3/20 0.38
GABRG3 Q99928 3/20 0.38
GABRQ Q9UN88 3/20 0.38
MCHR1 Q99705 1/20 0.36
NCF1 P14598 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15059859 0.81 POLB (0.47) POLBTDP1GABRPGABRDGABRA1
SCHEMBL27248062 0.79 POLB (0.62) POLBTDP1NPC1RAB9AMEN1
SCHEMBL4768119 0.76 PDCD1 (0.48) POLBTDP1GABRPGABRDGABRA1
SCHEMBL31128223 0.75 GABRP (0.60) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL20918539 0.74 POLB (0.44) POLBTDP1GABRPGABRDGABRA1
SCHEMBL20679536 0.72 NCF1 (0.40) POLBTDP1GABRPGABRDGABRA1
SCHEMBL13746013 0.71 NCF1 (0.42) TDP1MCHR1NCF1LMNANOS3
SCHEMBL8094722 0.70 MCHR1 (0.43) TDP1MCHR1NCF1LMNANOS3
SCHEMBL359862 0.70 MCHR1 (0.50) TDP1MCHR1NCF1LMNANOS3
SCHEMBL15544743 0.70 NOS2 (0.54) POLBGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10112928-B2 Inhibitors of SYK HOFFMANN-LA ROCHE INC. (US) 2018-10-30 US disclosed
EP-2802567-B1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS HOFFMANN LA ROCHE (CH) 2017-03-01 EP disclosed
EP-2802567-B1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS HOFFMANN LA ROCHE (CH) 2017-03-01 EP disclosed
US-20150284367-A1 INHIBITORS OF SYK HOFFMANN-LA ROCHE INC. 2015-10-08 US disclosed
US-20150284367-A1 INHIBITORS OF SYK HOFFMANN-LA ROCHE INC. 2015-10-08 US disclosed
US-20150284367-A1 INHIBITORS OF SYK HOFFMANN-LA ROCHE INC. 2015-10-08 US disclosed
EP-2909174-A1 INHIBITORS OF SYK F. Hoffmann-La Roche AG (CH) 2015-08-26 EP disclosed
US-8901124-B2 Pyridazine amide compounds useful as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2014-12-02 US disclosed
US-8901124-B2 Pyridazine amide compounds useful as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2014-12-02 US disclosed
US-8901124-B2 Pyridazine amide compounds useful as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2014-12-02 US disclosed
EP-2802567-A1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-11-19 EP disclosed
WO-2014060371-A1 INHIBITORS OF SYK F. HOFFMANN-LA ROCHE AG (CH) 2014-04-24 WO disclosed
WO-2014060371-A1 INHIBITORS OF SYK F. HOFFMANN-LA ROCHE AG (CH) 2014-04-24 WO disclosed
WO-2013104573-A1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-07-18 WO disclosed
WO-2013104573-A1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-07-18 WO disclosed
US-20130178478-A1 PYRIDAZINE AMIDE COMPOUNDS HOFFMAN-LA ROCHE INC. (US) 2013-07-11 US disclosed
US-20130178478-A1 PYRIDAZINE AMIDE COMPOUNDS HOFFMAN-LA ROCHE INC. (US) 2013-07-11 US disclosed
US-20130178478-A1 PYRIDAZINE AMIDE COMPOUNDS HOFFMAN-LA ROCHE INC. (US) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178478-A1 PYRIDAZINE AMIDE COMPOUNDS SYK, BTK, IRAK2 POLB 2886/4885TDP1 476/4885GABRP 1975/4885
US-20150284367-A1 INHIBITORS OF SYK SYK, BTK, LYN POLB 3159/4885TDP1 560/4885GABRP 3240/4885
US-10112928-B2 Inhibitors of SYK SYK, BTK, LYN POLB 3159/4885TDP1 560/4885GABRP 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.